[Tumor rejection antigen and cancer immunotherapy]

Area of Science:

• Immunology
• Oncology
• Biotechnology

Context:

• Tumor rejection antigens (TRAs) are recognized by cytotoxic T cells (CTLs) on various cancers, including murine tumors and human melanomas.
• Current immunotherapies involve cancer cell vaccines and adoptive transfer of CTLs/tumor-infiltrating lymphocytes (TILs).
• Recombinant tumor rejection antigens and heat shock proteins show promise as tumor antigens.

Purpose:

• To explore the potential of tumor rejection antigens (TRAs) as a basis for novel cancer immunotherapies.
• To investigate strategies for augmenting weak anti-tumor immune responses.
• To evaluate the efficacy of cytokine and gene therapies in cancer treatment.

Summary:

• Tumor rejection antigens (TRAs) recognized by cytotoxic T cells (CTLs) have been identified in several murine tumors and human malignant melanomas.
• Peptides derived from TRAs are being investigated as tumor vaccines for a new era of immunotherapy.
• Cancer cell vaccines and adoptive transfer of CTLs/TILs have shown success, with recombinant proteins also emerging as promising tumor antigens.
• Cytokine and gene therapies are being developed to enhance immune responses, with cytokines used directly or their genes introduced into tumor cells or CTLs/TILs.

Impact:

• Identified TRAs offer potential targets for developing effective cancer vaccines and immunotherapies.
• Recombinant proteins and HSPs represent promising avenues for tumor antigen-based therapies.
• The integration of cytokine and gene therapies could significantly boost anti-tumor immunity, leading to improved patient outcomes.